{
  "trial_id": "NCT01664182",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, histological subtype of renal cell carcinoma, prior anti-VEGF therapy, number of prior regimens, leukocyte count, absolute neutrophil count, platelet count, total bilirubin, AST/ALT levels, PTT/aPTT, INR, creatinine levels, urinary protein levels, blood pressure, presence of central nervous system metastases, history of thromboembolism, history of significant bleeding, cardiovascular disease history, surgical history, wound healing status, allergic reaction history, medication use, HIV status, ability to take oral medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "ECOG Performance Score",
          "ECOG performance status"
        ],
        [
          "Prior Anti-VEGF Agent",
          "prior anti-VEGF therapy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "histological subtype of renal cell carcinoma",
        "number of prior regimens",
        "leukocyte count",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin",
        "AST/ALT levels",
        "PTT/aPTT",
        "INR",
        "creatinine levels",
        "urinary protein levels",
        "blood pressure",
        "presence of central nervous system metastases",
        "history of thromboembolism",
        "history of significant bleeding",
        "cardiovascular disease history",
        "surgical history",
        "wound healing status",
        "allergic reaction history",
        "medication use",
        "HIV status",
        "ability to take oral medications"
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, histological subtype of renal cell carcinoma, prior anti-VEGF therapy, number of prior regimens, leukocyte count, absolute neutrophil count, platelet count, total bilirubin, AST/ALT levels, PTT/aPTT, INR, creatinine levels, urinary protein levels, blood pressure, presence of central nervous system metastases, history of thromboembolism, history of significant bleeding, cardiovascular disease history, surgical history, wound healing status, allergic reaction history, medication use, HIV status, ability to take oral medications."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Histological Subtype, Prior Anti-VEGF Therapy, Number of Prior Regimens, Leukocyte Count, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, AST/ALT Levels, PTT/aPTT, INR, Creatinine Levels, Urinary Protein Levels, Blood Pressure, Tumor Site Amenable to Biopsy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "ECOG Performance Score",
          "ECOG Performance Status"
        ],
        [
          "Prior Anti-VEGF Agent",
          "Prior Anti-VEGF Therapy"
        ]
      ],
      "remaining_reference_features": [],
      "remaining_candidate_features": [
        "Histological Subtype",
        "Number of Prior Regimens",
        "Leukocyte Count",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Total Bilirubin",
        "AST/ALT Levels",
        "PTT/aPTT",
        "INR",
        "Creatinine Levels",
        "Urinary Protein Levels",
        "Blood Pressure",
        "Tumor Site Amenable to Biopsy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Histological Subtype, Prior Anti-VEGF Therapy, Number of Prior Regimens, Leukocyte Count, Absolute Neutrophil Count, Platelet Count, Total Bilirubin, AST/ALT Levels, PTT/aPTT, INR, Creatinine Levels, Urinary Protein Levels, Blood Pressure, Tumor Site Amenable to Biopsy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Prior Anti-VEGF Therapy, Prior mTOR Inhibitor Therapy, Prior Investigational Therapy, Number of Prior Regimens, Time from Prior Anti-VEGF Therapy, Time from Prior mTOR Inhibitor Therapy, Time from Prior Investigational Therapy, Baseline Tumor Size, Baseline Hemoglobin, Baseline Platelet Count, Baseline Creatinine, Baseline Urinary Protein, Systolic Blood Pressure, Diastolic Blood Pressure.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "ECOG Performance Score",
          "ECOG Performance Status"
        ],
        [
          "Prior Anti-VEGF Agent",
          "Prior Anti-VEGF Therapy"
        ]
      ],
      "remaining_reference_features": [],
      "remaining_candidate_features": [
        "Prior mTOR Inhibitor Therapy",
        "Prior Investigational Therapy",
        "Number of Prior Regimens",
        "Time from Prior Anti-VEGF Therapy",
        "Time from Prior mTOR Inhibitor Therapy",
        "Time from Prior Investigational Therapy",
        "Baseline Tumor Size",
        "Baseline Hemoglobin",
        "Baseline Platelet Count",
        "Baseline Creatinine",
        "Baseline Urinary Protein",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Prior Anti-VEGF Therapy, Prior mTOR Inhibitor Therapy, Prior Investigational Therapy, Number of Prior Regimens, Time from Prior Anti-VEGF Therapy, Time from Prior mTOR Inhibitor Therapy, Time from Prior Investigational Therapy, Baseline Tumor Size, Baseline Hemoglobin, Baseline Platelet Count, Baseline Creatinine, Baseline Urinary Protein, Systolic Blood Pressure, Diastolic Blood Pressure."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, Karnofsky performance status, histological subtype of renal cell carcinoma, number of prior anti-VEGF regimens, time since prior anti-VEGF therapy, presence of sarcomatoid differentiation, presence of bone metastases, presence of liver metastases, lactate dehydrogenase (LDH) level, hemoglobin level, corrected calcium level, absolute neutrophil count, platelet count, creatinine level, urinary protein level, systolic blood pressure, diastolic blood pressure.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "ECOG Performance Score",
          "ECOG performance status"
        ],
        [
          "Prior Anti-VEGF Agent",
          "number of prior anti-VEGF regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Karnofsky performance status",
        "histological subtype of renal cell carcinoma",
        "time since prior anti-VEGF therapy",
        "presence of sarcomatoid differentiation",
        "presence of bone metastases",
        "presence of liver metastases",
        "lactate dehydrogenase (LDH) level",
        "hemoglobin level",
        "corrected calcium level",
        "absolute neutrophil count",
        "platelet count",
        "creatinine level",
        "urinary protein level",
        "systolic blood pressure",
        "diastolic blood pressure"
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, Karnofsky performance status, histological subtype of renal cell carcinoma, number of prior anti-VEGF regimens, time since prior anti-VEGF therapy, presence of sarcomatoid differentiation, presence of bone metastases, presence of liver metastases, lactate dehydrogenase (LDH) level, hemoglobin level, corrected calcium level, absolute neutrophil count, platelet count, creatinine level, urinary protein level, systolic blood pressure, diastolic blood pressure."
  }
}